

Barristers & Solicitors Ivor M. Hughes Rick Tuzi Jenene Roberts

Patent Agents Neil H. Hughes, P.Eng. Marcelo K. Sarkis, P.Eng. Wm. Kitt Sinden Samuel T. Tekie, P.Eng. Francis Ng-Cheng-Hin

Via Courier

The Commissioner of Patents United States Patent and Trademark Office Customer Service Window, Mail Stop Issue Fee Randolph Building 401 Dulany Street Alexandria, VA 22314 U.S.A.

Dear Sir:

Re:

United States Patent Application No. 10/580,011

of Tim Fat Tam, Michael Spino, Wanren Li, Yingsheng Wang,

Yanqing Zhao and Birenkumar Hasmukhbhai

for Cycloalkyl Derivatives of 3-Hydroxy-4 Pyridinones

Filed:

May 19, 2006

Due Date:

May 7, 2008

Customer No.: 23607

Pursuant to a Notice of Allowance dated February 7, 2008, a copy of which is enclosed for your reference, Applicant respectfully submits a cheque in the amount of U.S. \$1,740.00 made payable to the Director of the United States Patent and Trademark Office, comprising \$1,440.00 for the issue fee for a large entity and \$300.00 for the publication fee. If there should occur an overpayment or an underpayment of fees in respect of this application, the Commissioner is authorized to access Deposit Account No. 08-3255 to make the appropriate adjustments.

Applicant also submits a completed PTOL-85 Fee(s) Transmittal Form, in duplicate.

Also enclosed herewith is a stamped, self-addressed verification card which we request that you kindly acknowledge and return to this office at the earliest opportunity.



We thank the Commissioner for his cooperation in this regard and look forward to obtaining issue notification in this matter.

Respectfully submitted,

Kitt Sinden

Registration No. 50,188

Agent for Applicant

jf

Enclosures



Applicant(s) Application No.

MOEMAN	10/580,011	TAM ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Patricia L. Morris	1625	
The MAILING DATE of this communication appeal claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	plication. If not include will be mailed in due	ed course. THIS
1. This communication is responsive to <u>11/30/07</u> .			
2. X The allowed claim(s) is/are 1-12 and 16-18 (renumbered as 1-15).			
3.			
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. ☐ Notice of Informal F 6. ☐ Interview Summary Paper No./Mail Da 7. ☐ Examiner's Amenda 8. ☑ Examiner's Statema 9. ☐ Other <u>See Continua</u>	(PTO-413), te, ment/Comment ent of Reasons for Alle	owance

Continuation of Attachment(s) 9. Other: Drawings filed 5/19/06 are accepted.

10/580,011 Art Unit: 1625

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: The prior art does not teach or suggest the presence of at least on cycloalkyl group on the nitrogen atom of the dihydropyridine ring or on the nitrogen atom of the carboxamide substituent.

Claims 1-12 are directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claim 18, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, all the diseases set forth in claim 18 are hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on November 2, 2007 is hereby withdrawn with respect to the method of uses. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

10/580,011

Art Unit: 1625

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia L. Morris whose telephone number is (571) 272-0688.

The examiner can normally be reached on Mondays through Fridays.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Patricia L. Morris
Primary Examiner

Art Unit 1625

plm

February 4, 2007